NANOTEC and GPO to upgrade drug innovation in Thailand
To support projected growth of pharma market in the region
The partnership will help upgrade the research capabilities of the two Thai agencies and promote national competitiveness, said Soontorn Vorakul, acting managing director for the GPO.
‘The focus of the research collaboration will be in the area of cosmeceutical and drug delivery using nanotechnology,’ he said.
Professor Sirirurg Songsivilai, executive director of NANOTEC, added that the opportunities for nanotechnology in pharmaceutical manufacturing and development are enormous.
‘It is clear that the international pharmaceutical industry has embraced nanotechnology research in their manufacturing. It is essential for the GPO and NANOTEC to join forces and share expertise if we are to keep pace with drug discovery,’ he said.
Thailand will be the eighth largest economy in the Asia Pacific region by 2016, according to the Economist Intelligence Unit (EIU). GDP growth is projected to increase to 7.1% in the same period.
The EIU also projects an annual growth rate of around 0.7% and the population to be the ninth largest in the Asia Pacific region in five years’ time. The elderly population is also rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region by 2016.
By 2016 it is estimated that Thailand will have the seventh largest pharmaceutical market in the Asia Pacific region.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
The path to commercial allogeneic iPSC therapies
Read moreThe cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines